Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...

Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

ResMed Inc. reported its Q4 2025 earnings, revealing a robust financial performance with revenue reaching $1.35 billion, surpassing the forecast of $1.33 billion. Despite this positive financial ...

ResMed Inc. (NYSE:RMD) Q4 2025 Earnings Call Transcript July 31, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.55, expectations were $2.49. Operator: Hello, and welcome to the Q4 ...

Ty is an experienced writer, editor, journalist, and online opinion-haver. He has been reviewing cars and covering automotive news full-time for nearly a decade for outlets such as Gear Patrol, Inside ...

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company’s ...

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has ...

ResMed’s EPS and revenue exceeded forecasts for Q2 FY2025. Stock price declined 6.6% in after-hours trading despite strong earnings. ResMed launched new products and expanded its digital health ...